Skip to main navigation Skip to search Skip to main content

Potent neutralization by antibodies targeting the MPXV A28 protein

  • Ron Yefet
  • , Leandro Battini
  • , Mathieu Hubert
  • , Katya Rakayev
  • , Florence Guivel-Benhassine
  • , Noam Rattner
  • , Francoise Porrot
  • , Lilach Abramovitz
  • , Gilad Ostashinsky
  • , Noam Ben-Shalom
  • , Jeanne Postal
  • , Ksenia Polonsky
  • , Maya Ralph-Altman
  • , Sireen Sweed
  • , Tal Korner
  • , Nadav Friedel
  • , David Hagin
  • , Eli Sprecher
  • , Zvi Fishelson
  • , Oren Kobiler
  • Lihi Adler-Abramovich, Olivier Schwartz*, Pablo Guardado-Calvo*, Natalia T. Freund*
*Corresponding author for this work
  • Université Paris Cité
  • Tel Aviv University
  • Tel Aviv Sourasky Medical Center

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Monkeypox virus (MPXV) is the most pathogenic Poxvirus in circulation, yet key viral antigens remain immunologically unexplored. We isolate and characterize a panel of monoclonal antibodies (mAbs) targeting MPXV A28 (OPG153), an important membranal protein present on mature MPXV virions. From male convalescent individuals, we isolate anti-A28 mAbs alongside additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralize MPXV and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High-resolution crystal structures of two anti-A28 mAbs, 10M2146 and 8M2110, in complex with VACV A26 reveal two distinct and highly conserved proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 modestly attenuates disease in infected female mice. Moreover, immunization with A28 elicits antigen-specific B cells and robust neutralizing antibody responses and provides protection against lethal VACV challenge. These findings identify MPXV A28 as a promising central target for the induction of neutralizing antibodies and antiviral interventions.

Original languageEnglish
Article number11455
JournalNature Communications
Volume16
Issue number1
DOIs
StatePublished - Dec 2025

Funding

FundersFunder number
Agence Nationale de Recherches sur le Sida et les Hépatites Virales
RICF
LEAPS
Israel Institute for Biological Research
VACV-IHDJ-vFire
Sagol Center for Regenerative Medicine
Ariel Porat
Fondation pour la Recherche Médicale
Institut Pasteur
Tel Aviv University
Edmond J. Safra Center for Bioinformatics
United States - Israel Binational Science FoundationBMGF INV-058519, 01031771
Agence Nationale de la RechercheANR-24-CE15-6625, ANR-22-CE11-0003
Israel Science Foundation638/23, 3136/22
Vaccine Research InstituteANR-10-LABX-77
Labex IBEIDANR-10-LABX-62-IBEID, 101102733

    Fingerprint

    Dive into the research topics of 'Potent neutralization by antibodies targeting the MPXV A28 protein'. Together they form a unique fingerprint.

    Cite this